阿仑单抗是一种兔源人化CD52抗原的单克隆抗体。在粘合后阿仑单抗可以产生持久的抗原消除作用，其已经成功用于器官移植后的免疫诱导治疗。我们对在威斯康辛大学采用阿仑单抗诱导的胰肾联合移植的患者进行单中心的回顾性调查，并和采用巴利昔单抗诱导的患者进行病例对照的研究。供者及受者的人口统计学、患者生存率、肾脏或胰腺移植物的存活率、肾脏移植物功能延迟恢复、EB病毒感染、BK病毒感染、PTLD和脓毒血症无明显差异。而在阿仑单抗治疗组中，CMV病毒感染的发生率明显升高。考虑到明显增高的CMV病毒感染发生率，我们改变了诱导治疗的方案：采用单一30mg剂量的阿仑单抗提到两次剂量。该调整的长期效果依然需要进一步观察。该研究中的结果认为：阿仑单抗的早期较低的费用以及各种近期严重不良反应的低发生率，使其成为我中心SPK患者的诱导治疗药物。

Alemtuzumab is a humanized, rat monoclonal antibody directed against the CD52 antigen. After binding, alemtuzumab causes profound and durable depletion and has been successfully used as immune induction therapy for organ transplantation. This was a single center, retrospective review of patients who underwent simultaneous pancreas-kidney transplantation at the University of Wisconsin using alemtuzumab induction therapy compared with historical controls that received induction with basiliximab. There were no differences in donor or recipient demographics, rates of patient survival, renal or pancreas allograft survival, renal allograft delayed graft function, EBV infection, BKV infection, PTLD or sepsis. There was a statistically significant increase in the incidence of cytomegalovirus (CMV) infection in the alemtuzumab-treated group. Given the significantly higher incidence of CMV infections, we have since altered our induction protocol to consist of a single 30 mg dose of alemtuzumab instead of two doses. The long-term effects of this change remain to be seen. Due to the results seen in this study, the low initial cost of the drug and the absence of any severe, short-term side effects, alemtuzumab has been selected as the induction drug of choice at our center for patients undergoing SPK.